Clinical Trial Update: PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial [Phase 2]

View source ↗

Summary

A single-arm Phase 2 clinical trial evaluating PD-1 antibody plus lenvatinib and TACE-HAIC for potentially resectable hepatocellular carcinoma is in progress, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• PD-1 antibody (PD-1 inhibitor)
• TACE-HAIC

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN